Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.

ABSTRACT:

Objective

To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic therapy (biologic-experienced population).

Perspective and setting

UK National Health Service (NHS).

Methods

The model was structured as a 3-month decision tree leading into a Markov model. Comparators were licensed tumour necrosis factor inhibitors (including available biosimilars) and CC in the biologic-naïve and biologic-experienced populations, respectively. Clinical parameters captured treatment response, short-term disease activity and patient functioning, as well as long

SUBMITTER: Emery P 

PROVIDER: S-EPMC6021464 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature